Nemera expands its insulin pen’s offer in Brazil
This partnership expands offer of diabetes medicines in the country;
Nemera’s Advapen launch happens under the trade name Lifepen® for the administration of Glargilin insulin for the treatment of diabetes
A pioneer in biotechnological medicines in Brazil, BIOMM is launching Nemera’s Advapen under the trade name Lifepen®
for the administration of Glargilin insulin for the treatment of
diabetes.
Nemera and Biomm sign partnership agreement to commercialize reusable insulin pen in Brazil
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance